The double edge of cancer immunotherapy.
D000818:Animals; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000150:complications / Q000453:epidemiology; D015897:Comorbidity; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects* / Q000379:methods; D007249:Inflammation / Q000139:chemically induced / Q000150:complications / Q000453:epidemiology; D000074324:Ipilimumab / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy*; D018579:Patient Selection; D011379:Prognosis; D012107:Research Design
D000074324:Ipilimumab